Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

Rizzo, J. Douglas; Lichtin, Alan E.; Woolf, Steven H.; Seidenfeld, Jerome; Bennett, Charles L.; Cella, David; Djulbegoviĉ, Benjamin; Goode, Matthew J.; Jakubowski, Ann A.; Lee, Stephanie J.; Miller, Carole B.; Rarick, Mark U.; Regan, David H.; Browman, George P.; Gordon, Michael

doi:10.1182/blood-2002-06-1767

Cited by 292 publications

(294 citation statements)

References 58 publications

Supporting

Mentioning

276

Contrasting

Unclassified

Order By: Relevance

“…The ability of erythropoietin to stimulate the production of red blood cells has led to the use of recombinant human erythropoietin for the prevention or treatment of anemia in cancer patients. 33 The benefits of recombinant human erythropoietin in patients with cancer-related anemia include increased hemoglobin levels, reduced transfusion requirements and improved quality of life. [34][35][36][37][38] In patients with prostate cancer, the presence of anemia may be associated with a significant reduction in survival.…”

Section: Discussionmentioning

confidence: 99%

Erythropoietin and erythropoietin receptor expression in human prostate cancer

et al. 2005

View full text Add to dashboard Cite

Erythropoietin is a hematopoietic cytokine that regulates the production of red blood cells. Erythropoietin is normally produced in the adult kidney in a hypoxia-inducible manner. The recombinant form of human erythropoietin is in clinical use for the prevention and treatment of anemia that is associated with cancer and its treatment with chemoradiation therapy. A series of recent studies from our laboratory and others have reported the expression of receptors for erythropoietin in several different types of human cancer cells. In the present study, we investigated the expression of erythropoietin receptor and its ligand erythropoietin in human prostate cancer. In clinical specimens of prostate cancer, we found abundant expression of erythropoietin receptor protein in all primary tumors examined using immunohistochemistry. Furthermore, we observed erythropoietin coexpression in prostate cancer cells by immunohistochemical analysis. To determine whether monolayer cultures of continuous cell lines derived from prostate cancer also express erythropoietin receptor and erythropoietin, we studied well-characterized hormone-responsive (LNCaP) and hormone-refractory (PC-3) prostate cancer cell lines. We performed reverse-transcription and polymerase chain reaction assays to detect erythropoietin receptor and erythropoietin mRNA transcripts, and also immunoprecipitation and immunoblotting to detect erythropoietin receptor protein expression in prostate cancer cells. These experiments revealed the expression of both erythropoietin receptor and erythropoietin in LNCaP and PC-3 cells suggesting that these prostate cancer cell lines may serve as useful experimental models for further studies of erythropoietin and erythropoietin receptor function in prostate cancer. The coexpression of erythropoietin receptor and its ligand erythropoietin in human prostate cancer cells suggests the potential for growth regulation by erythropoietin-erythropoietin receptor in an autocrine or paracrine manner.

show abstract

Section: Discussionmentioning

confidence: 99%

Erythropoietin and erythropoietin receptor expression in human prostate cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…EPO is the main regulator for erythropoiesis [S(t)] where S max is the maximum stimulation of responses by EPO and SC 50_Rat is the EPO concentration producing half maximum stimulation. The differential equations for each cell population are: (5) (6) (7) (8) and the pharmacologic/physiologic function for EPO is: (9) The erythroid progenitor cells and proerythroblasts have a high capacity for DNA synthesis, and thus they were considered to be the primary cellular target in the erythroid lineage. The cytotoxic metabolite (M) of carboplatin is assumed responsible for hematopoietic toxicity in bone marrow (Eq.…”

Section: Pk/pd Analysismentioning

confidence: 99%

“…In addition, the importance of baseline hemoglobin values at the start of erythropoietic therapy and the timing of erythropoietic treatment relative to application of chemotherapy have been recognized [1,7,8]. Murine or rodent anemia models following chemotherapeutic agents aid in evaluating effects of erythropoietic agents in various settings.…”

Section: Introductionmentioning

confidence: 99%

Pharmacodynamic model for chemotherapy-induced anemia in rats

Woo

Krzyzanski

Jusko

2007

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Anticancer agents often cause bone marrow toxicity resulting in progressive anemia which may influence the therapeutic effects of erythropoietic-stimulating agents. The objective of this study was to develop a pharmacodynamic (PD) model to describe chemotherapy-induced anemia in rats. Anemia was induced in male Wistar rats with a single intravenous (i.v.) injection of 60 mg/kg carboplatin. Hematological responses including reticulocytes, red blood cells (RBC), hemoglobin, and endogenous rat erythropoietin (EPO) were measured for up to 4 weeks. A catenary, lifespanbased, indirect response model served as a basic PD model to represent erythroid cellular populations in the bone marrow and blood involved in erythropoiesis. The model assumed that actively proliferating progenitor cells in the bone marrow are sensitive to anti-cancer agents and subject to an irreversible removal process. The removal rate of the target cells is proportional to drug activity concentrations and the cell numbers. An additional RBC loss from the circulation resulting from thrombocytopenia was described by a first-order process. The turnover process of rat EPO and EPOmediated feedback inhibition mechanism regulated by hemoglobin changes were incorporated. Reticulocyte counts decreased rapidly and reached a nadir by day 3 after administration of carboplatin and returned to the baseline by day 13. This was followed by a gradual increase and the rebound peak occurred at about day 15. The hemoglobin nadir was approximately 9 g/dl observed at about 11-13 days compared to its normal value of 13 g/dl and hemoglobin returned to the baseline by day 30. The increase in endogenous rat EPO mirrored inversely hemoglobin changes and the maximum increase was observed soon after the hemoglobin nadir. The carboplatin-treated rats exhibited progressive anemia. The proposed model adequately described the time course of hematological changes after carboplatin in rats and can be a useful tool to explore potential strategies for the management of anemia caused by chemotherapy.

show abstract

“…The ASCO/ASH guidelines provide a thorough overview of the use of epoetin alfa therapy in patients with various forms of cancer based on data included in an evidence report assembled by the Blue Cross Blue Shield Association Technology Evaluation Center [38]. The panel reviewed and summarized many clinical studies involving patients with solid tumors or hematologic malignancies and with chemotherapy-or cancer-related anemia.…”

Section: Clinical Practice Guidelines For the Use Of Epoetin Alfa In mentioning

confidence: 99%

“…Evidence-based clinical practice guidelines for the use of epoetin alfa in patients with cancer have been developed by the American Society of Clinical Oncology (ASCO) in conjunction with ASH [38] and by the National Comprehensive Cancer Network (NCCN) [39]. The ASCO/ASH guidelines provide a thorough overview of the use of epoetin alfa therapy in patients with various forms of cancer based on data included in an evidence report assembled by the Blue Cross Blue Shield Association Technology Evaluation Center [38].…”

Section: Clinical Practice Guidelines For the Use Of Epoetin Alfa In mentioning

confidence: 99%

New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications

Weiss¹

2003

The Oncologist

View full text Add to dashboard Cite

Recombinant human erythropoietin (epoetin alfa) has proven beneficial for the treatment of various anemias. The mechanism of action of endogenous erythropoietin and the therapeutic use of epoetin alfa to stimulate red blood cell production and improve the quality of life in cancer patients are reviewed here. Epoetin alfa may also attenuate the cognitive dysfunction associated with cancer therapy. Interestingly, functional endogenous erythropoietin receptor signaling pathways have been demonstrated in numerous nonerythropoietic tissues. Of particular importance, epoetin alfa confers neurotrophic and neuroprotective effects in cultured neurons and in several animal models for neurologic disease. In one clinical trial, epoetin alfa appeared to limit functional and histologic damage in patients with stroke. Therefore, in cancer patients receiving chemotherapy, the beneficial effects of epoetin alfa could be mediated not only through enhanced erythrocyte production but also via direct effects on the nervous system. Further investigation into the nonerythropoietic effects of epoetin alfa could broaden its clinical utility for patients with cancer and also provide new therapies for various neurologic disorders. The Oncologist 2003;8(suppl 3):18-29 The Oncologist 2003;8(suppl 3):18-29 www.TheOncologist.com

show abstract

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

Cited by 292 publications

References 58 publications

Erythropoietin and erythropoietin receptor expression in human prostate cancer

Erythropoietin and erythropoietin receptor expression in human prostate cancer

Pharmacodynamic model for chemotherapy-induced anemia in rats

New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications

Contact Info

Product

Resources

About